Sergliflozin etabonate
Modify Date: 2025-08-25 14:22:02
Sergliflozin etabonate structure
|
Common Name | Sergliflozin etabonate | ||
|---|---|---|---|---|
| CAS Number | 408504-26-7 | Molecular Weight | 448.463 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 611.5±55.0 °C at 760 mmHg | |
| Molecular Formula | C23H28O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 206.8±25.0 °C | |
Use of Sergliflozin etabonateSergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1]. |
| Name | ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate |
|---|---|
| Synonym | More Synonyms |
| Description | Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1]. |
|---|---|
| Related Catalog | |
| Target |
SGLT2 |
| In Vivo | Sergliflozin etabonate (1、3、10、30 mg/kg；口服；一次) 以剂量依赖性方式显着降低 KK-Ay 小鼠的非空腹血糖水平[1]。 Sergliflozin etabonate (1.7、8.4、45.7 mg/kg饲料含有 0.001、0.005 和 0.025% sergliflozin etabonate；进食；每天服用，持续 9 周) 以剂量依赖的方式降低非空腹血糖水平并降低肝脏中的甘油三酯含量 在 KK-Ay 小鼠中[1]。 Animal Model: 14 weeks, Female KK-Ay mice[1] Dosage: 1, 3, 10, 30 mg/kg Administration: Oral; once Result: Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively. Animal Model: 4 weeks, Female KK-Ay mice[1] Dosage: 1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate Administration: Fed, daily for 9 weeks Result: Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 611.5±55.0 °C at 760 mmHg |
| Molecular Formula | C23H28O9 |
| Molecular Weight | 448.463 |
| Flash Point | 206.8±25.0 °C |
| Exact Mass | 448.173340 |
| PSA | 123.91000 |
| LogP | 3.62 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.581 |
| β-D-Glucopyranoside, 2-[(4-methoxyphenyl)methyl]phenyl 6-O-(ethoxycarbonyl)- |
| 2-(4-Methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside |
| Sergliflozin etabonate |
| Sergliflozin |